OAB and LUTS: Individualising treatment can significantly improve patients’ quality of life
23 Dec 2019
At a recent Pfizer-sponsored symposium, held in conjunction with the 17th Urological Association of Asia Congress at Kuala Lumpur Convention Centre, Professor Bannakij Lojanapiwat gave a lecture on the pathophysiology and management of overactive bladder (OAB) and lower urinary tract symptoms (LUTS), highlighting the importance of individualised pharmacological intervention in optimizing patient outcomes.
